NM_000249.4:c.793C>T

Variant summary

Our verdict is Pathogenic.
>+14 Pathogenic
-7
-6
-1
0
+5
+6
+9
+10
B
LB
VUS
LP
P
The variant received 24 classification points (ACMG Germline Pathogenicity v2019). PS3PS4_SupportingPM1PM2PM5PP1PP3_StrongPP5_Very_Strong

The NM_000249.4(MLH1):c.793C>T (p.Arg265Cys) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a cumulative frequency of 0.000000684 (AC=1) in the gnomAD database across 1,461,428 control chromosomes (no homozygotes observed). The grpmax filtering allele frequency (95% CI) is 0.0000009. In-silico predictor (REVEL) classifies this variant as likely damaging/oncogenic. Splicing prediction tools (SpliceAI) predict no significant impact on normal splicing. The affected nucleotide is highly conserved across species (PhyloP 100-way vertebrate score: 7.28). Variant has been reported in ClinVar as Pathogenic/Likely Pathogenic (★★★). ClinVar reports functional evidence for this variant: "SCV000262499: RNA analysis indicates that this missense change induces altered splicing and may result in an absent or altered protein product. Studies have shown that this missense change alters mRNA splicing and is expected to lead to the loss of protein expression (PMID:18561205, 22736432, 26247049" and additional evidence is available in ClinVar. A different missense at the same amino acid position has been reported as Pathogenic/Likely Pathogenic in ClinVar: p.R265V: Pathogenic (ClinVar VariationId 619508, 1 star) Other variants at the same amino acid position have been reported in ClinVar (not pathogenic): p.R265H: Conflicting_classifications_of_pathogenicity (ClinVar VariationId 90381, 1 star); p.R265L: Uncertain_significance (ClinVar VariationId 1928288, 2 stars); p.R265= (synonymous): Likely_benign (ClinVar VariationId 491730, 2 stars) This exact variant is established as oncogenic in: CGI (Cancer Genome Interpreter). This exact variant is curated in the UniProt human variants database as Uncertain Significance, associated with Colorectal cancer, hereditary nonpolyposis, type 2 (hnpcc2); it is also listed as a COSMIC curated somatic variant.

Frequency

Genomes: not found (cov: 32)
Exomes 𝑓: 0 ( 0 hom. )

Consequence

MLH1
NM_000249.4 missense, splice_region

Predictors

18
1
REVEL: 0.97 : Pathogenic

Clinical Significance

Pathogenic reviewed by expert panel P:25U:1O:1

Conservation

PhyloP100: 7.28

Publications

1 publications found
Genes affected
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
MLH1 Gene-Disease associations (from GenCC):
  • Lynch syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, G2P, ClinGen
  • Lynch syndrome 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Ambry Genetics
  • Muir-Torre syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: G2P, Ambry Genetics, Genomics England PanelApp
  • mismatch repair cancer syndrome 1
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Orphanet, Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae)
  • Lynch syndrome 1
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • ovarian cancer
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • malignant pancreatic neoplasm
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • rhabdomyosarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • prostate cancer
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
  • breast cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
  • hereditary breast carcinoma
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
RPL29P11 (HGNC:36905): ()

Genome browser will be placed here

new If you want to explore the variant's impact on the transcript NM_000249.4, check out the Mutation Effect Viewer. This is especially useful for frameshift variants or if you want to visualize the effect of exon loss / intron retention.

Classification according to ACMG Germline Pathogenicity v2019

Classification was made for transcript:

Our verdict: Pathogenic. The variant received 24 points.

PS3Functional studies show damaging effect
Well-established functional study supports damaging effect (PS3); SCV000262499: RNA analysis indicates that this missense change induces altered splicing and may result in an absent or altered protein product. Studies have shown that this missense change alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 18561205, 22736432, 26247049; internal data).; SCV000276047: RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data).; SCV000279078: Published functional studies demonstrate a damaging effect: aberrant splicing and reduced mRNA and protein expression as well as deceased protein stability and reduced binding of MLH1 to PMS2 (PMID: 12386821, 15713769, 18205192, 20864636, 22753075, 21952876, 26761715); Observed in individuals with personal or family histories consistent with pathogenic variants in MLH1 and concordant tumor studies (PMID: 10495924, 12011148, 12386821, 12547705, 15849733, 15926618, 17312306, 19526325, 19698169, 19419416, 20045164, 20587412, 20682701, 21642682, 21404117, 21952876, 24710284, 26248088, 26202870, 30521064, 35534704); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 17210669, 20020535, 18561205, 22824075, 20045164, 21404117, 20682701, 19224586, 21681552, 20864636, 28127413, 15731775, 21952876, 11781295, 11555625, 17594722, 22736432, 22949387, 22753075, 17135187, 23760103, 10495924, 16995940, 15849733, 12547705, 19698169, 26247049, 22843852, 24710284, 21642682, 16216036, 19526325, 20587412, 25345868, 17312306, 21155023, 26053027, 26248088, 17192056, 15926618, 12011148, 26202870, 23741719, 16830052, 15713769, 12386821, 17510385, 26761715, 25081409, 11948175, 28445943, 30274973, 31589614, 32849802, 31332305, 18205192, 33260537, 29758216, 24362816, 31447099, 30787465, 30521064, 31830689, 19419416, 35534704, 31391288, 40118241); SCV000592378: This variant has been tested in different functional assays at the protein level, with results that were not always consistent; the p.Arg265Cys was associated with a mild reduction of mismatch repair efficiency in four studies (Plotz 2006; Ellison 2001; Wanat 2007; Takahashi 2007) but not in a fifth one (Trojan 2002) (Tournier 2007).; SCV000684870: Functional studies have shown that this variant significantly decreases MLH1 protein stability (PMID: 18205192) and the ability of MLH1 protein to bind PMS2 (PMID: 21952876). This variant has also been shown to affect mRNA splicing (PMID: 12386821, 15713769, 18561205).; (+6 more)
PS4Prevalence increased in affected individuals
Rare variant reported in affected individuals by ≥2 independent ClinVar submitters (PS4_Supporting); 11 ClinVar submitter(s) report the variant in affected individuals; SCV000043791: In affected members of 13 Taiwanese families with hereditary nonpolyposis colorectal cancer (LYNCH2; 609310), Tang et al.; SCV000262499: This missense change has been observed in individual(s) with colorectal cancer or Lynch syndrome (PMID: 12386821, 15713769, 19419416, 20587412, 20864636).; SCV000276047: This mutation has been identified in several individuals who met Amsterdam I/II criteria for Lynch syndrome (Trojan, 2002; Wolf, 2005; Woods, 2010; Hardt, 2011; Ambry internal data). In addition, this mutation has been identified in multiple probands whose Lynch syndrome-associated tumor demonstrated high microsatellite instability and/or loss of MLH1/PMS2 expression by immunohistochemistry (Li, 2020; Ambry internal data).; SCV000279078: Published functional studies demonstrate a damaging effect: aberrant splicing and reduced mRNA and protein expression as well as deceased protein stability and reduced binding of MLH1 to PMS2 (PMID: 12386821, 15713769, 18205192, 20864636, 22753075, 21952876, 26761715); Observed in individuals with personal or family histories consistent with pathogenic variants in MLH1 and concordant tumor studies (PMID: 10495924, 12011148, 12386821, 12547705, 15849733, 15926618, 17312306, 19526325, 19698169, 19419416, 20045164, 20587412, 20682701, 21642682, 21404117, 21952876, 24710284, 26248088, 26202870, 30521064, 35534704); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 17210669, 20020535, 18561205, 22824075, 20045164, 21404117, 20682701, 19224586, 21681552, 20864636, 28127413, 15731775, 21952876, 11781295, 11555625, 17594722, 22736432, 22949387, 22753075, 17135187, 23760103, 10495924, 16995940, 15849733, 12547705, 19698169, 26247049, 22843852, 24710284, 21642682, 16216036, 19526325, 20587412, 25345868, 17312306, 21155023, 26053027, 26248088, 17192056, 15926618, 12011148, 26202870, 23741719, 16830052, 15713769, 12386821, 17510385, 26761715, 25081409, 11948175, 28445943, 30274973, 31589614, 32849802, 31332305, 18205192, 33260537, 29758216, 24362816, 31447099, 30787465, 30521064, 31830689, 19419416, 35534704, 31391288, 40118241); SCV000592378: One large study of Tawainese patients demonstrated that the p.Arg265Cys variant was identified in 13 out of 93 unrelated families. In total, 93 cancers were noted in these 13 families including 66 with cases of colon cancer, 6 cases of rectal cancer, 3 cases of endometrial cancer, 6 cases of gastric cancer, 1 case of ovarian cancer and 11 cases of other types of cancer (Tang 2009).; (+6 more)
PM1Mutational hot spot or critical domain
Missense neighbourhood hotspot (≥2 P/LP within ±8 AA, OR ≥ 5 vs. background) — PM1; In-domain: 0 pathogenic, 0 benign rare missense variants; ±8 AA neighbourhood: 3 pathogenic, 3 benign (OR vs. background: 5.0)
PM2Absent/extremely low in population databases
Very rare in gnomAD for AD/XL gene (popmax AF < threshold/10) — PM2; GnomAD popmax AF = 0.0000009 — very rare for AD+AR gene (base 0.0001, raised to 0.0005 by highest known P/LP ClinVar AF 0.000636) — PM2 moderate
PM5Novel missense at known pathogenic residue
Different pathogenic missense at same AA residue in ClinVar (PM5); ClinVar contains a germline Pathogenic/Likely Pathogenic entry at the same amino acid position with a different amino acid change: p.R265V: Pathogenic (ClinVar VariationId 619508, 1 star); Other variants at the same amino acid residue (not pathogenic): p.R265H: Conflicting_classifications_of_pathogenicity (ClinVar VariationId 90381, 1 star); p.R265L: Uncertain_significance (ClinVar VariationId 1928288, 2 stars); p.R265= (synonymous): Likely_benign (ClinVar VariationId 491730, 2 stars)
PP1Cosegregation with disease
ClinVar submission reports cosegregation with disease (PP1); SCV000262499: It has also been observed to segregate with disease in related individuals.; SCV000276047: This mutation has also been shown to segregate with disease in several families meeting Amsterdam I/II criteria (De Jong, 2004; Tang, 2009; Sjursen, 2010).; SCV000731294: It segregated with disease in at least 12 family members (Hardt 2011, Tang 2009).; SCV004176523: This variant has been observed to segregate with disease (Tang R, et. al., 2009).
PP3Computational evidence supports damaging effect
Germline meta computational scorer (REVEL/MetaRNN/BayesDel) predicts damaging effect — strong evidence (PP3); Splicing verdict: not pathogenic; Germline computational verdict: pathogenic (Strong)
PP5Reputable source reports pathogenic
ClinVar ≥3 stars pathogenic — very strong (PP5); ClinVar submissions overwhelmingly pathogenic (≥10 total, ≥80% P/LP, <10% B/LB) — strong (PP5, count-based); ClinVar germline classification: Pathogenic/Likely Pathogenic, 3 star(s). ClinVar submissions strongly and reliably favor pathogenicity (24/25 total P/LP)

Variant Effect in Transcripts

Automated classification analysis was done for transcript: NM_000249.4. You can select a different transcript below to see updated classification assignments.

RefSeq Transcripts

MLH1 NM_000249.4
MANE Select
HGVSc / HGVSpc.793C>Tp.Arg265Cys
Exon rankExon 10 of 19
missensesplice_region
Prot: NP_000240.1
MLH1 NM_001354628.2
HGVSc / HGVSpc.793C>Tp.Arg265Cys
Exon rankExon 10 of 18
missensesplice_region
Prot: NP_001341557.1
MLH1 NM_001354629.2
HGVSc / HGVSpc.694C>Tp.Arg232Cys
Exon rankExon 9 of 18
missensesplice_region
Prot: NP_001341558.1

Ensembl Transcripts

MLH1 ENST00000231790.8
MANE Select
HGVSc / HGVSpc.793C>Tp.Arg265Cys
Exon rankExon 10 of 19
missensesplice_region
Prot: ENSP00000231790
MLH1 ENST00000458205.7
TSL:1
HGVSc / HGVSpc.70C>Tp.Arg24Cys
Exon rankExon 11 of 20
missensesplice_region
Prot: ENSP00000402667
MLH1 ENST00000931189.2
HGVSc / HGVSpc.793C>Tp.Arg265Cys
Exon rankExon 10 of 19
missensesplice_region
Prot: ENSP00000601248

Frequencies

Allele frequencies (AF), counts (AC/AN), homozygotes and coverage

Common (AF > 0.05 / Hom > 5)
Rare (AF ≤ 0.0001 / Hom ≤ 1)
Global population databases 5 sources
GnomAD3 genomes
Cov:32
GnomAD4 exome
AF: 6.84e-7
AC:1
Hom:0
AN:1461428
Cov:31
GnomAD4 genome
Cov:32
TOPMed (Bravo)
AF: 0.00000378
AC:1
Hom:0
AN:264690
ALFA (dbGaP/dbSNP Allele Frequency Aggregator)
AF: 0.0000175
AC:1
Hom:0
AN:57126
Showing 5 sources

Case/control cohorts

CohortCasesControls
AFACANAFACAN
Epi25
(Epilepsy)
0.0000238 141956 0.00 066876
SCHEMA
(Schizophrenia)
0.00 048008 0.0000135 173916
Showing 2 cohortsAllele count / allele number. *AF is computed from the counts for ASC (not provided by the source).

ClinVar

ClinVar submissions
Significance:Pathogenic
Revision:reviewed by expert panel
View on ClinVar
Pathogenic
VUS
Benign
Condition
7
1
-
not provided (8)
6
-
-
Colorectal cancer, hereditary nonpolyposis, type 2 (6)
3
-
-
Lynch syndrome (3)
2
-
-
Carcinoma of colon (2)
2
-
-
Hereditary cancer-predisposing syndrome (2)
1
-
-
Hereditary nonpolyposis colon cancer (1)
1
-
-
Hereditary nonpolyposis colorectal neoplasms (1)
1
-
-
Inherited MMR deficiency (Lynch syndrome) (1)
1
-
-
Lynch syndrome 1 (2)
1
-
-
Muir-Torré syndrome;C1333991:Colorectal cancer, hereditary nonpolyposis, type 2;C5399763:Mismatch repair cancer syndrome 1 (1)

Computational Scores

AlphaGenome AVI
Pathogenic35
AlphaMissense
Pathogenic0.99
BayesDel_addAF
Pathogenic0.57D
BayesDel_noAF
Pathogenic0.59
CADD
Pathogenic33
DANN
Pathogenic1.0
DEOGEN2
Pathogenic0.90D
Eigen
Pathogenic1.1
Eigen_PC
Pathogenic1.0
FATHMM_MKL
Pathogenic1.0D
FuncVEP CTI
Pathogenic1.0
GPN-Star LLR
N/A-8.5
GPN-Star score
N/A8.5
LIST_S2
Pathogenic0.99D
M_CAP
Pathogenic0.72D
MetaRNN
Pathogenic0.99D
MetaSVM
Pathogenic0.94D
Mutation Taster
N/A0/100disease causing (ClinVar)
MutationAssessor
Pathogenic4.8H
PhyloP100
Uncertain7.3
popEVE
Benign-4.0
PrimateAI
Uncertain0.72T
PROVEAN
Pathogenic-7.8D
RBP_binding_hub_radar
N/A0.0
RBP_regulation_power_radar
N/A1.7
REVEL
Pathogenic0.97
Sift
Pathogenic0.0D
Sift4G
Pathogenic0.0D
Varity_R
N/A0.96
VESM-3B
Benign-12
Showing 30 of 30 scores

Splicing Scores

Pangolin (max)
Uncertain0.34
Pangolin loss
Uncertain0.34
Position offset: -2
SpliceAI score (max)
Benign0.15
Details are displayed if max score is > 0.2
Showing 3 of 3 scores

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.

MaveDB functional evidence

MaveDB is a public repository of laboratory assays that test the effect of thousands of variants at once — treat this as supporting research data and interpret it with great caution; it is not a clinical classification.

No MaveDB functional evidence found for this variant.

Publications

Other links and lift over

dbSNP: rs63751194;
hg19: chr3-37058999;
COSMIC: COSV51616044;
COSMIC: COSV51616044;
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.